A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation

Subotheni Thavaneswaran(The University of Sydney), David M. Thomas(New South Wales Department of Health), Lucille Sebastian(Heidelberg University), Rosemary Harrup(University of Tasmania), Michael D. Brown(University of Maryland, Baltimore), Min Huang(Shanghai Children's Hospital), Peter Grimison(The University of Sydney), Kenneth J. O’Byrne(Translational Research Institute), Frank Lin(The University of Sydney), John P. Grady(Garvan Institute of Medical Research), Adnan Nagrial(Westmead Hospital), Chee Khoon Lee(The University of Sydney), Jayesh Desai(Peter MacCallum Cancer Centre), Michael Millward(The University of Western Australia), Maya Kansara(Garvan Institute of Medical Research), Anthony M. Joshua(St Vincent's Hospital Sydney), Tony Mersiades(The University of Sydney), David Espinoza(The University of Sydney), Paul Craft(Canberra Hospital), John Simes(The University of Sydney), Sarah Chinchen(The University of Sydney)
npj Precision Oncology
September 9, 2024
10.1038/s41698-024-00698-4
Cited by 6

Related Papers

Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
|Stroke|2019|7.2k
2018 Guidelines for the Early Management of Patients With Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association
|Stroke|2018|5.5k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k